Compare CENT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CENT | DFTX |
|---|---|---|
| Founded | 1955 | N/A |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | CENT | DFTX |
|---|---|---|
| Price | $36.56 | $17.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $50.00 | $40.25 |
| AVG Volume (30 Days) | 58.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.77 | $14.62 |
| 52 Week High | $41.25 | $19.62 |
| Indicator | CENT | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 54.04 |
| Support Level | $34.52 | $16.26 |
| Resistance Level | $38.34 | $18.21 |
| Average True Range (ATR) | 0.90 | 0.94 |
| MACD | -0.49 | 0.11 |
| Stochastic Oscillator | 12.08 | 46.93 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).